TrialClinical genitourinary cancer2015

A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.

Srikala S Sridhar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.